News

Why Iovance Biotherapeutics stock is back in focus after Q2 earnings Iovance Biotherapeutics (IOVA) is back on investor radars after its second quarter 2026 earnings. The company reported higher revenue and a reduced net loss, and it reaffirmed full year revenue guidance. The quarter was driven by Amtagvi and Proleukin sales, and by progress across Iovance Biotherapeutics pipeline programs, including new regulatory approvals and Fast Track designations for lifileucel in certain soft tissue...

Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy.

Moby summary of Iovance Biotherapeutics, Inc.'s Q2 2026 earnings call

Iovance Biotherapeutics Inc (IOVA) reports record Q2 2026 revenue of $99.3 million, driven by strong Amtagvi demand and all-time high gross margins of 56%.

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The

Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL) therapy AMTAGVI and expanding commercial execution. Management also reiterated that recent manu

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?